All 10 drugmakers agree to negotiate Medicare drug prices despite legal challenges
- All manufacturers of the first 10 drugs chosen for Medicare price negotiations have agreed to participate in the talks.
- The selected drugs accounted for $3.4 billion in out-of-pocket costs for Medicare enrollees last year.
- The negotiations are a result of President Biden's Inflation Reduction Act, with reduced prices taking effect in 2026.
- Some drugmakers are suing to try to stop the negotiations but agreed to comply to avoid penalties.
- Medicare will continue selecting more drugs each year for price negotiations aimed at lowering costs.